NASDAQ · ORMP
Oramed Pharmaceuticals Inc.
$4.23+$0.07 (+1.68%)
Oramed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.67% below the high.
Loading market information…
TLV · CGEN.TA · ILA
Stock price, earnings
Quote as of Oct 29, 2026, 03:24 PM UTC. Cached market data; not a live quote.
One-year closing-price history · ILA. Historical prices are not a forecast.
Compugen Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Compugen Ltd.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -ILA 0.25. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Compugen Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Compugen Ltd. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of innovative therapeutic candidates across Israel, the United States, and Europe. The company's primary focus is immuno-oncology, with a robust pipeline of investigational treatments. Key assets in their immuno-oncology portfolio include: COM701, an anti-PVRIG antibody, currently in Phase I clinical trials for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, also in Phase I, being evaluated as a monotherapy in patients with advanced malignancies. Bapotulimab, an antibody designed to target ILDR2, which is undergoing Phase I clinical study for solid tumors. AZD2936, a novel bispecific antibody that targets both TIGIT and PD-1, advancing through Phase I/II clinical studies in patients with advanced or metastatic non-small cell lung cancer. Beyond these clinical-stage programs, Compugen is also pursuing early-stage immuno-oncology research, with a particular emphasis on myeloid targets. The company maintains significant strategic alliances, including: A collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against Compugen's proprietary immune checkpoint regulators. A partnership with Bristol-Myers Squibb to assess the safety and tolerability of COM701 when combined with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in advanced solid tumor patients. An engagement with Johns Hopkins School of Medicine to explore novel T cell and myeloid checkpoint targets. A licensing agreement with AstraZeneca for the development of bispecific and multispecific immuno-oncology antibody products. A research collaboration with Johns Hopkins University focusing on myeloid research. Compugen Ltd. was founded in 1993 and is headquartered in Holon, Israel.
Latest available per-share figures in ILS. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 19, 2025 | -ILA 0.30-45.45% vs estimate | ILA 8.51M-28.46% vs estimate |
|---|
| Q4 2024 | Mar 4, 2025 | -ILA 0.26-315.42% vs estimate | ILA 5.36M-88.7% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | ILA 0.01-90.91% vs estimate | ILA 63.81M+1,235.94% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.23+$0.07 (+1.68%)
Oramed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.67% below the high.
₪0.84-₪0.01 (-0.59%)
Novolog (Pharm-Up 1966) Ltd’s quoted price sits in the lower half of its reported 52-week range, 39.71% below the high.
₪0.18+₪0.00 (+0.57%)
Bonus BioGroup Ltd.’s quoted price sits in the lower half of its reported 52-week range, 71.1% below the high.
₪0.46-₪0.01 (-1.72%)
BATM Advanced Communications Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.27% below the high.
₪1.11₪0.00 (0.0%)
Dna Group (T.R.) Ltd’s quoted price sits in the lower half of its reported 52-week range, 26.8% below the high.
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
₪27.94₪0.00 (0.0%)
Kadimastem Ltd’s quoted price sits in the lower half of its reported 52-week range, 47.51% below the high.
₪3.96-₪0.02 (-0.43%)
Pluri Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.42% below the high.
